Olins Biotech: The Gldburk vaccine is expected to unblind in the first half of this year, and we are confident in completing it on schedule.

At the annual shareholders meeting of Orin Biotech held recently, regarding the unblinding of the gold-plated fungus vaccine and the disclosure of external nodes of concern to the market, Orin Biotech told reporters that the company will strictly follow the plan disclosed earlier to advance relevant work. After completing the preparation work before unblinding, such as the report from the Central Inspection Institute, data cleaning, and the blinded review meeting, it is expected that the unblinding will be implemented and progress will be publicly disclosed as scheduled in the first half of this year. The company said that all work is progressing smoothly, and no unexpected or unforeseen circumstances that may affect the plan have arisen, expressing confidence in completing the process on time.